Christopher D Lao

  • 3776 Citations
  • 15 Scopus h-Index
20042021

Fingerprint Fingerprint is based on mining the text of the person's scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.

  • 1 Similar Profiles
Melanoma Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Neoplasms Medicine & Life Sciences
nivolumab Medicine & Life Sciences
ipilimumab Medicine & Life Sciences
Merkel Cell Carcinoma Medicine & Life Sciences
Survival Medicine & Life Sciences
Clinical Trials Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Grants 2005 2021

Research Output 2004 2017

  • 3776 Citations
  • 15 Scopus h-Index
  • 28 Article
  • 6 Letter
  • 5 Review article
  • 2 Comment/debate

A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607)

Kalinsky, K., Lee, S., Rubin, K. M., Lawrence, D. P., Iafrarte, A. J., Borger, D. R., Margolin, K. A., Leitao, M. M., Tarhini, A. A., Koon, H. B., Pecora, A. L., Jaslowski, A. J., Cohen, G. I., Kuzel, T. M., Lao, C. D. & Kirkwood, J. M. Jul 15 2017 In : Cancer. 123, 14, p. 2688-2697 10 p.

Research output: Research - peer-reviewArticle

Melanoma
Extremities
Research
Neoplasms
Dasatinib
Merkel Cell Carcinoma
Clinical Trials
Neoplasms
nivolumab
Publications
1 Citations

Health-related quality of life results from the phase III CheckMate 067 study

Schadendorf, D. , Larkin, J. , Wolchok, J. , Hodi, F. S. , Chiarion-Sileni, V. , Gonzalez, R. , Rutkowski, P. , Grob, J. J. , Cowey, C. L. , Lao, C. , Wagstaff, J. , Callahan, M. K. , Postow, M. A. , Smylie, M. , Ferrucci, P. F. , Dummer, R. , Hill, A. , Taylor, F. , Sabater, J. , Walker, D. & 3 others Kotapati, S., Abernethy, A. & Long, G. V. Sep 1 2017 In : European Journal of Cancer. 82, p. 80-91 12 p.

Research output: Research - peer-reviewArticle

Quality of Life
nivolumab
ipilimumab
Therapeutics
Melanoma
1 Citations

Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: Final update of the pivotal ERIVANCE BCC study

Sekulic, A., Migden, M. R., Basset-Seguin, N., Garbe, C., Gesierich, A., Lao, C. D., Miller, C., Mortier, L., Murrell, D. F., Hamid, O., Quevedo, J. F., Hou, J., McKenna, E., Dimier, N., Williams, S., Schadendorf, D., Hauschild, A. & and for the ERIVANCE BCC Investigators May 16 2017 In : BMC Cancer. 17, 1, 332

Research output: Research - peer-reviewArticle

HhAntag691
Basal Cell Carcinoma
Safety
Research Personnel
Survival
2 Citations

Neurologic serious adverse events associated with nivolumab plus ipilimumab or nivolumab alone in advanced melanoma, including a case series of encephalitis

Larkin, J., Chmielowski, B., Lao, C. D., Hodi, F. S., Sharfman, W., Weber, J., Suijkerbuijk, K. P. M., Azevedo, S., Li, H., Reshef, D., Avila, A. & Reardon, D. A. Jun 1 2017 In : Oncologist. 22, 6, p. 709-718 10 p.

Research output: Research - peer-reviewArticle

Encephalitis
Nervous System
Melanoma
ipilimumab
nivolumab